Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. In a double-blind, placebo-controlled trial conducted from 1998 ...

Objective: To present management options for gynaecomastia and mastodynia associated with nonsteroidal antiandrogen therapy, supported by relevant data and case studies. Background: Gynaecomastia ...

Adding antiandrogen therapy to radiotherapy as a salvage treatment for men with biochemical recurrence following prostatectomy improves outcomes. It extends overall survival (OS) and reduces the ...

The addition of 24 months of antiandrogen therapy with bicalutamide to radiation therapy improved OS among patients with prostate cancer who have evidence of disease recurrence following radical ...

A protein that confers a worse prognosis in bladder cancer when present in high levels may be regulated by androgens, suggesting a role for antiandrogen agents in the treatment of this disease.

Paris – Das Antiandrogen Darolutamid kann bei Patienten mit einem nicht-metasta­siertem Prostatakarzinom, bei denen es unter einer Hormontherapie (Androgen­deprivation) zu einem erneuten ...

A nearly two-decades-long clinical trial has demonstrated that adding antiandrogen therapy to radiation therapy can improve the survival of prostate cancer patients who have evidence of disease ...